Inhalation Sciences presents comprehensive new strategy update

Report this content

(Stockholm, Sweden, 24 May 2022) On 24 May Inhalation Sciences AB presented a major strategy update on its plans and goals for growth at RedEye in Stockholm Sweden. Watch the presentation here.

Watch the full presentation, by CEO Manoush Masarrat and Chairman Daniel Spasic, here:  

Daniel Spasic, Chairman of the Board: “We are confident in the company’s future and believe absolutely that our current strategy will create growth and value moving ahead.”

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.